Blueprint Medicines is acquiring Lengo Therapeutics for $250 million. The company is developing new small-molecule precision therapeutics targeting driver mutations in oncology. Blueprint Medicines will also pay an additional $215 million if the investigational drug LNG-451, which could potentially treat non-small cell lung cancer patients with exon insertion mutations, achieves certain targets. The application to the FDA for the clinical trial is scheduled to be filed by the end of 2021.